CD73 Inhibitor Compounds for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer, infections, and neurodegenerative diseases are limited by the immunosuppressive effects of CD73, which promotes tumor progression, immune evasion, and therapy resistance, and there is a need for effective inhibitors to target this enzyme.
Innovation Solution
Development of compounds according to Formulas (I), (II), (IIa), (III), and (IV) or their pharmaceutically acceptable salts, solvates, or stereoisomers that act as CD73 inhibitors, useful for treating cancers, infections, and neurodegenerative diseases by inhibiting the CD73 enzyme and reducing adenosine production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for cancer, infections, and neurodegenerative diseases are used, then existing therapeutic options are available, but treatment effectiveness is limited by immunosuppressive effects of CD73
Solution Approach 1:
The patent extracts and targets the specific harmful function of CD73 enzyme in the disease process. By designing compounds that specifically bind to and inhibit CD73, the invention removes the immunosuppressive effect from the system, allowing existing treatments to work more effectively without being counteracted by CD73-mediated immune suppression.
Solution Approach 2:
The patent applies preliminary anti-action by pre-administering or co-administering CD73 inhibitors with existing cancer, infection, or neurodegenerative disease treatments. This preliminary blocking of CD73 prevents the enzyme from exerting its harmful immunosuppressive effects during the course of treatment, thereby enhancing the overall therapeutic effectiveness.
2Ease of manufacture
If CD73 activity is not inhibited, then existing treatments can be administered, but tumor progression and immune evasion are promoted
Solution Approach 1:
The patent introduces CD73 inhibitor compounds as intermediary substances that mediate between the existing treatments and the disease process. These small molecule inhibitors act as mediators that block the CD73-adenosine axis, preventing tumor cells and pathogens from exploiting this pathway for immune evasion, while allowing the primary treatments to proceed unchanged.
3Reliability
If CD73 inhibitors are developed, then immune responses against cancer and infections can be enhanced, but new compound development is required
Solution Approach 1:
The patent employs parameter changes by systematically varying key structural parameters of the inhibitor compounds, including the heterocyclic core (Q1-Q2 configuration), substituent groups (W, Z, R1-R10), and linker regions (X, Y). By optimizing these molecular parameters, the invention achieves high-affinity binding to CD73 and potent immune response enhancement while managing the complexity through structured molecular design.
Data Source
AI summary
Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.